Answers are grounded in this paper and cite their sources.
Intervertebral disc degeneration (IVDD) is a leading cause of low back pain (LBP) worldwide, yet no current therapy can prevent or reverse its progression. Nucleus pulposus (NP) fibrosis has emerged as a critical pathological feature of IVDD. This review systematically summarizes the current understanding of the mechanisms underlying NP fibrosis and explores advances in targeted therapeutic strategies. During IVDD, the NP undergoes profound extracellular matrix (ECM) remodeling characterized by progressive loss of aggrecan and type II collagen (COL II), accompanied by pathological accumulation of type I collagen (COL I), fibronectin, and small leucine-rich proteoglycans (SLRPs). This matrix transformation is driven by activated matrix-degrading enzymes, including matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs), and by the phenotypic transition of resident NP cells toward fibroblast-like and myofibroblast states. Single-cell transcriptomic studies have revealed increasing cellular heterogeneity during degeneration, with expansion of fibrotic subpopulations and identification of novel markers such as fibroblast activation protein α (FAPα), fibroblast-specific protein 1 (FSP1), and α-smooth muscle actin (α-SMA). The fibrotic cascade is orchestrated by multiple signaling pathways, including transforming growth factor β (TGF-β)/small mothers against decapentaplegic (SMAD), Ras homolog family member A (RhoA)/myocardin-related transcription factor A (MRTF-A), and Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ)-TEA domain transcription factor (TEAD), which are activated by mechanical stress, inflammatory mediators, and intercellular crosstalk among disc cells, immune cells, and endothelial cells. Notably, specific profibrotic macrophage subsets play a central role through the secreted phosphoprotein 1 (SPP1)‑cluster of differentiation 44 (CD44) axis and other communication networks. Preclinical strategies targeting profibrotic pathways have shown promise, yet the challenge remains to suppress chronic pathological fibrosis without ablating beneficial reparative responses. Future directions include standardizing fibrotic cell nomenclature, elucidating the transition from adaptive to maladaptive fibrosis, and developing stage-specific interventions guided by precise biomarkers. Achieving this balance represents the central opportunity for advancing intervertebral disc (IVD) regeneration and repair.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: